STOCK MARKET BSE NSE

Bharat Biotech's rotavirus vaccine, Rotavac 5D receives WHO Prequalification

Rotavac 5D's formulation allows it to be administered without a buffer and its low dose volume facilitates vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination.

Published: 02nd August 2021 05:25 PM  |   Last Updated: 02nd August 2021 05:25 PM   |  A+A-

Bharat Biotech logo

The first generation rotavac was developed under a public-private partnership between Bharat Biotech and various partners, making it the largest ever social innovation project in the world.

By PTI

HYDERABAD: Bharat Biotech on Monday announced that the World Health Organisation (WHO) has awarded prequalification to its rotavirus vaccine, Rotavac 5D to prevent rotavirus diarrhoea, a press release from the company said.

The new variant of Rotavac, Rotavac 5D, is a unique rotavirus vaccine formulation that can be administered without a buffer and its low dose volume (0.5 mL) facilitates easy vaccine logistics, cold chain management and low biomedical waste disposal post-vaccination, it said.

The vaccine is used for the prevention of rotavirus infection, which is prevalent in infants and young children.

WHO Prequalification enables the procurement of Rotavac 5D by agencies such as UNICEF and PAHO (Pan American Health Organisation) and will fast-track global access to this life-saving vaccine.

Suchitra Ella, Joint Managing Director, Bharat Biotech, said, ROTAVAC and Rotavac 5Dare projects were conceived, innovated and executed in India, in collaboration with Indian and global partners.

"Today's announcement is an important step to further strengthen and fulfil Bharat Biotech's vision to address neglected diseases and prevent infections that continue to affect millions in the developing world," she said.

Bharat Biotech developed the first generation, rotavirus vaccine, Rotavac under a Public-Private Partnership with the Department of Biotechnology, Government of India and 16 other international partners, making it the largest ever social innovation project for public health.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

edexworks
flipboard facebook twitter whatsapp